Biotech fundraising boom continues with CureVac IPO
GlobalCapital, is part of the Delinian Group, DELINIAN (GLOBALCAPITAL) LIMITED, 4 Bouverie Street, London, EC4Y 8AX, Registered in England & Wales, Company number 15236213
Copyright © DELINIAN (GLOBALCAPITAL) LIMITED and its affiliated companies 2024

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Biotech fundraising boom continues with CureVac IPO

CureVac_Covid-19_Vaccine_ PA_575_375

Germany’s CureVac has gone public on the Nasdaq, joining the army of biotech companies that have tapped the equity capital markets for cash during the pandemic, despite growing concern of a brewing dot-com style bubble.

Unlock this article.

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Request a Free Trial or Login
Gift this article